NCT01943305View on ClinicalTrials.gov

The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

December 31, 2015

Conditions
Yellow FeverEncephalitis, Japanese
Interventions
BIOLOGICAL

Japanese Encephalitis vaccine

IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart

BIOLOGICAL

Yellow Fever vaccine

STAMARIL, 1 dose (0.5 ml)

Trial Locations (1)

169608

Singhealth Investigational Medicine Unit, Singapore

All Listed Sponsors
collaborator

Duke-NUS Graduate Medical School

OTHER

lead

Singapore General Hospital

OTHER

NCT01943305 - The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans | Biotech Hunter | Biotech Hunter